Skip to main content

Table 2 Treatment-related adverse events: all grades occurring in ≥2 patients and grade 3-5a occurring in any patient

From: Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer

Treatment-related adverse events (N = 22)

All grades n (%)

Grade 3-5a n (%)

All

18 (82)

1 (5)

Diarrhea

7 (32)

0

Fatigue

4 (18)

0

Pruritus

3 (14)

0

Rash

3 (14)

0

Decreased appetite

2 (9)

0

Headache

2 (9)

0

Cough

2 (9)

0

Pneumonitis

2 (9)

0

Colitis

1 (5)

1 (5)

  1. aThere were no grade 4 or 5 treatment-related adverse events